open access

Vol 15, No 3 (2019)
Case report
Published online: 2019-06-26
Get Citation

The usefulness of an 18F-FDG-PET/MR examination in a patient with rectal and breast cancer. A case report

Rafał Maksim, Ewa Sierko, Dominika Hempel, Justyna Burzyńska- Śliwowska, Kamila Kidrycka, Piotr Szumowski, Marek Z. Wojtukiewicz, Krystian Kidrycki, Tomasz Filipowski, Małgorzata Mojsak
DOI: 10.5603/OCP.2019.0015
·
Oncol Clin Pract 2019;15(3):180-184.

open access

Vol 15, No 3 (2019)
CASE REPORT
Published online: 2019-06-26

Abstract

Recently, we have gained access to innovative radiological and metabolic examination methods. One of these methods is PET/MRI with fluorodeoxyglucose (18F-FDG) tracer. Performing this innovative examination in a 69-year-old woman with diagnosed rectal cancer brought additional benefits. The use of PET/MRI resulted in precise clinical staging, the detection of a synchronous early-stage right breast cancer, and in the optimisation of treatment of both cancers. To date, diagnostic guidelines concerning rectal and breast cancers do not recommend the use of functional imaging for routine imaging.

Abstract

Recently, we have gained access to innovative radiological and metabolic examination methods. One of these methods is PET/MRI with fluorodeoxyglucose (18F-FDG) tracer. Performing this innovative examination in a 69-year-old woman with diagnosed rectal cancer brought additional benefits. The use of PET/MRI resulted in precise clinical staging, the detection of a synchronous early-stage right breast cancer, and in the optimisation of treatment of both cancers. To date, diagnostic guidelines concerning rectal and breast cancers do not recommend the use of functional imaging for routine imaging.

Get Citation

Keywords

PET/MR; rectal cancer; breast cancer

About this article
Title

The usefulness of an 18F-FDG-PET/MR examination in a patient with rectal and breast cancer. A case report

Journal

Oncology in Clinical Practice

Issue

Vol 15, No 3 (2019)

Article type

Case report

Pages

180-184

Published online

2019-06-26

DOI

10.5603/OCP.2019.0015

Bibliographic record

Oncol Clin Pract 2019;15(3):180-184.

Keywords

PET/MR
rectal cancer
breast cancer

Authors

Rafał Maksim
Ewa Sierko
Dominika Hempel
Justyna Burzyńska- Śliwowska
Kamila Kidrycka
Piotr Szumowski
Marek Z. Wojtukiewicz
Krystian Kidrycki
Tomasz Filipowski
Małgorzata Mojsak

References (12)
  1. Battersby N, How P, Moran B, et al. Prospective validation of a low rectal cancer magnetic resonance imaging staging system and development of a local recurrence risk stratification model. Annals of Surgery. 2016; 263(4): 751–760.
  2. Bujko K, Herman R, Pałucki J et al. Rak odbytnicy, aktualizacja na dzień 02.12.2015. In: Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych. Tom I. Krzakowski M, Warzocha K et al. (ed.). Via Medica, Gdańsk 2013; 199 .
  3. NCCN Clinical Practice Guidelines in Oncology, Rectal Cancer, Version 3.2018.
  4. Sasaki K, Kawasaki H, Sato M, et al. Impact of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Uptake on Preoperative Positron Emission Tomography/Computed Tomography in the Lymph Nodes of Patients with Primary Colorectal Cancer. Dig Surg. 2017; 34(1): 60–67.
  5. Brush J, Boyd K, Chappell F, et al. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation. Health Technol Assess. 2011; 15(35): 1–192, iii.
  6. Magometschnigg HF, Baltzer PA, Fueger B, et al. Diagnostic accuracy of (18)F-FDG PET/CT compared with that of contrast-enhanced MRI of the breast at 3 T. Eur J Nucl Med Mol Imaging. 2015; 42(11): 1656–1665.
  7. Vercher-Conejero JL, Pelegrí-Martinez L, Lopez-Aznar D, et al. Positron emission tomography in breast cancer. Diagnostics (Basel). 2015; 5(1): 61–83.
  8. Huzarski T, Górecka-Szyld B, Huzarska J, et al. Polish Hereditary Breast Cancer Study Group. Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer. Hered Cancer Clin Pract. 2017; 15: 4.
  9. Jacobs L, Meek DB, van Heukelom J, et al. Comparison of MRI and colonoscopy in determining tumor height in rectal cancer. United European Gastroenterol J. 2018; 6(1): 131–137.
  10. Dimitriou N, Michail O, Moris D, et al. Low rectal cancer: Sphincter preserving techniques-selection of patients, techniques and outcomes. World J Gastrointest Oncol. 2015; 7(7): 55–70.
  11. Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005; 23(33): 8469–8476.
  12. Kowalski ES, Cohen JD, Snider JW, et al. Positron emission tomography/computed tomography (PET/CT) in the initial evaluation of women with nonmetastatic breast cancer can frequently alter management. Int J Radiat Oncol Biol Phys. 2017; 99(2): E25–E26.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl